Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Verrica Pharmaceuticals (VRCA) Other financing activities (2022 - 2024)

Verrica Pharmaceuticals (VRCA) has 3 years of Other financing activities data on record, last reported at $163000.0 in Q3 2024.

  • For Q3 2024, Other financing activities rose 167.21% year-over-year to $163000.0; the TTM value through Sep 2024 reached $163000.0, down 14.21%, while the annual FY2022 figure was $17000.0, N/A changed from the prior year.
  • Other financing activities reached $163000.0 in Q3 2024 per VRCA's latest filing, up from -$173000.0 in the prior quarter.
  • Across five years, Other financing activities topped out at $163000.0 in Q3 2024 and bottomed at -$173000.0 in Q4 2023.
  • Average Other financing activities over 3 years is $25714.3, with a median of $17000.0 recorded in 2022.
  • The widest YoY moves for Other financing activities: up 458.82% in 2023, down 1117.65% in 2023.
  • A 3-year view of Other financing activities shows it stood at $17000.0 in 2022, then tumbled by 1117.65% to -$173000.0 in 2023, then surged by 194.22% to $163000.0 in 2024.
  • Per Business Quant database, its latest 3 readings for Other financing activities were $163000.0 in Q3 2024, -$173000.0 in Q4 2023, and $61000.0 in Q3 2023.